A. A. H. P. Megens
Department of Discovery Research
Johnson & Johnson Pharmaceutical Research and Development
B-2340 Beerse
Belgium
Name/email consistency: high
- Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist. Megens, A.A., Ashton, D., Vermeire, J.C., Vermote, P.C., Hens, K.A., Hillen, L.C., Fransen, J.F., Mahieu, M., Heylen, L., Leysen, J.E., Jurzak, M.R., Janssens, F. J. Pharmacol. Exp. Ther. (2002)